Capricor Therapeutics, Inc. (CAPR): who owns it and who trades it
As of Nov 16, 2026, CAPR insiders reported 9 open-market sales worth $6.8M and no purchases in the last 12 months, with 89% of the sale value made under pre-set 10b5-1 plans. The largest seller was Karimah Es Sabar (Director), with $3.8M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Capricor Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CAPR
169 funds and institutions reported CAPR shares worth $1B at the end of Q2 2026, about 71% of the company. The largest holder is BlackRock, Inc. with 7.2%.
Funds and institutions (13F) 71%Everyone else 29%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 4.15M | 7.21% | $99.8M | +21% |
| Tang Capital Management LLC | 4.10M | 7.13% | $98.7M | +21% |
| Montanova Capital, LLC | 4.09M | 7.12% | $98.6M | +7% |
| State Street Corp | 3.40M | 5.91% | $81.8M | +56% |
| Vanguard Capital Management LLC | 2.30M | 4.00% | $55.3M | +13% |
| Goldman Sachs Group Inc | 1.58M | 2.74% | $38M | +73% |
| California State Teachers Retirement System | 1.53M | 2.66% | $63.5M | +2262% |
| Ra Capital Management, L.P. | 1.51M | 2.62% | $36.3M | No change |
| Boxer Capital Management, LLC | 1.40M | 2.43% | $33.6M | +136% |
| Geode Capital Management, LLC | 1.37M | 2.39% | $33M | +23% |
| FMR LLC (Fidelity) | 1.14M | 1.98% | $27.4M | +47% |
| Citadel Advisors LLC | 814,444 | 1.42% | $19.6M | +51% |
| Mercer Global Advisors Inc | 802,732 | 1.40% | $19.3M | +99% |
| Soleus Capital Management, L.P. | 761,737 | 1.32% | $18.3M | – |
| Morgan Stanley | 684,515 | 1.19% | $16.5M | +62% |
| Vanguard Portfolio Management LLC | 636,087 | 1.11% | $15.3M | +68% |
| UBS Group AG | 619,661 | 1.08% | $14.9M | +67% |
| DG Capital Management, LLC | 611,595 | 1.06% | $14.7M | +56% |
| Ikarian Capital, LLC | 604,215 | 1.05% | $14.5M | +14% |
| Northern Trust Corp | 503,532 | 0.88% | $12.1M | +21% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CAPR insiders reported $0 of open-market purchases and $6.8M of sales. 89% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Karen Krasney | Vice president | Sale | 24,100 | $30.38 | $732K | Form 4 |
| Jun 24, 2026 | Karen Krasney | Vice president | Sale | 400 | $30.00 | $12K | Form 4 |
| Jun 22, 2026 | Karen Krasney | Vice president | Sale | 500 | $30.00 | $15K | Form 4 |
| May 1, 2026 | Karen Krasney | Vice president | Sale plan | 25,000 | $31.70 | $792K | Form 4 |
| Apr 2, 2026 | Karimah Es Sabar | Director | Sale plan | 7,529 | $32.00 | $241K | Form 4 |
| Apr 1, 2026 | Karimah Es Sabar | Director | Sale plan | 53,735 | $31.03 | $1.7M | Form 4 |
| Mar 31, 2026 | Karen Krasney | Vice president | Sale plan | 25,000 | $30.12 | $753K | Form 4 |
| Mar 31, 2026 | Karimah Es Sabar | Director | Sale plan | 61,265 | $30.17 | $1.8M | Form 4 |
| Mar 31, 2026 | Anthony Bergmann | CFO | Sale plan | 25,000 | $30.13 | $753K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Karimah Es Sabar | Director | – | $3.8M | Apr 2, 2026 |
| Karen Krasney | EVP, GENERAL COUNSEL | – | $2.3M | Jun 25, 2026 |
| Anthony Bergmann | CHIEF FINANCIAL OFFICER | – | $753K | Mar 31, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CAPR short interest
Very high short interest. 32.3% of CAPR shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 72%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.77M CAPR shares were sold short, 32.3% of the shares outstanding, down 5.5% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 7.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.77M | 32.28% | -6% | 2.54M | 7.4 |
| Oct 15, 2026 | 19.86M | 34.16% | +5% | 3.02M | 6.6 |
| Sep 30, 2026 | 18.83M | 32.38% | -4% | 4.17M | 4.5 |
| Sep 15, 2026 | 19.68M | 33.85% | -11% | 3.32M | 5.9 |
| Aug 31, 2026 | 22.18M | 38.16% | +25% | 11.14M | 2.0 |
| Aug 14, 2026 | 17.75M | 30.54% | +11% | 10.83M | 1.6 |
| Jul 31, 2026 | 15.98M | 27.79% | +3% | 7.75M | 2.1 |
| Jul 15, 2026 | 15.58M | 27.09% | +6% | 1.44M | 10.8 |
| Jun 30, 2026 | 14.74M | 25.63% | +26% | 2.00M | 7.4 |
| Jun 15, 2026 | 11.70M | 20.35% | +6% | 854,754 | 13.7 |
| May 29, 2026 | 11.07M | 19.25% | +1% | 774,846 | 14.3 |
| May 15, 2026 | 10.92M | 18.98% | +4% | 1.33M | 8.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Capricor Therapeutics company events
Capricor Therapeutics filed 15 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Aug 24, 2026AnnouncementCapricor Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act target action date for its Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, from… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 30, 2026AnnouncementThe U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy, a rare and life-threatening disease for… Filing
- Jul 29, 2026AnnouncementCapricor Therapeutics, Inc. issued a press release announcing the publication in The Lancet of the final one-year results from its HOPE-3, Phase 3 clinical trial evaluating Deramiocel, its investigational cell therapy for the treatment of Duchenne muscular dystrophy. Filing
- Jul 14, 2026AgreementCapricor Therapeutics, Inc. entered into a Lease Agreement with ARE-SD Region No. 39 Owner, LLC for approximately 171,000 rentable square feet located at 9625 Towne Centre Drive, San Diego, California, to be used as Capricor’s new headquarters, including expanded manufacturing cleanrooms, research… Filing
- Jun 26, 2026AnnouncementCapricor Therapeutics, Inc. issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License Application seeking approval of… Filing
- Jun 8, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 7, 2026AnnouncementCapricor announced that it has filed a Complaint for Equitable Relief and Application for Preliminary Injunction in the Superior Court of New Jersey, Chancery Division, Bergen County. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 10, 2026AnnouncementAs disclosed above, the FDA has lifted the previously issued CRL and resumed review of the Company’s BLA seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of DMD cardiomyopathy. Filing
- Dec 5, 2025AnnouncementCapricor Therapeutics, Inc., a Delaware corporation, entered into an underwriting agreement with Piper Sandler & Co. and Oppenheimer & Co. Inc. as representatives of the underwriters, pursuant to which the Company agreed to sell and issue, in a public offering, an aggregate of 6,000,000 shares of… Filing
- Dec 3, 2025AnnouncementShared information with investors. Filing
- Dec 3, 2025AnnouncementAs disclosed above, the Company announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Capricor Therapeutics financials
Famous investors that hold CAPR
3 of the 50 well-known investors we track reported holding CAPR in their latest 13F filing. The largest position is Israel Englander's, worth $15.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.67M | $15.8M | 0.0% | +614% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 671,505 | $6.4M | 0.0% | +609% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 62,600 | $593K | 0.0% | -92% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CAPR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G/A | 0.0% |
| Nov 16, 2026 | TANG CAPITAL MANAGEMENT, LLC | 13G/A | 0.0% |
| Nov 13, 2026 | Montanova Capital, LLC | 13G/A | 0.0% |
| Nov 13, 2026 | Montanova Capital, LLC | 13G/A | 0.0% |
| Oct 14, 2026 | Millennium Management LLC | 13G/A | 2.9% |
| Oct 14, 2026 | Millennium Management LLC | 13G/A | 2.9% |
Questions about Capricor Therapeutics, Inc. (CAPR) stock
Who owns the most CAPR stock?
The largest reported owner of Capricor Therapeutics, Inc. (CAPR) is BlackRock, Inc., with 7.2% of the company. In total, 169 funds and institutions reported holding CAPR at the end of Q2 2026, together about 71% of the shares. See the largest owners.
Are CAPR insiders buying or selling?
In the last 12 months, CAPR insiders reported no open-market purchases and 9 sales worth $6.8M. The latest trade was on Jun 25, 2026. See every trade.
What is the short interest in CAPR?
As of Oct 30, 2026, 18.77M CAPR shares were sold short, 32.3% of the shares outstanding, down 5.5% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 7.4 trading days (days to cover). See the history.
Which famous investors hold CAPR?
3 of the 50 well-known investors we track reported CAPR in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $15.8M. See all holders.
Executive pay
Capricor Therapeutics's chief executive was paid a total of $3.5M for the year ended Dec 31, 2025, up 129% from $1.5M the year before. In the last 12 months, Capricor Therapeutics's executives and directors bought no stock on the open market and sold $6.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.